The mechanisms that mediate implantation of the human embryo remain poorly understood and represent a fundamental problem in reproductive biology. Candidate molecules that mediate and facilitate implantation have been identified in animal studies, and include heparin binding epidermal growth factor. Here we demonstrate a potential function for the transmembrane form of heparin-binding epidermal growth factor in mediating blastocyst attachment to the endometrium, in two different novel in vitro models for human implantation. Furthermore, we demonstrate specific localisation of the heparin-binding epidermal growth factor receptor ErbB4, on the surface of the trophectoderm in peri-implantation human blastocysts. Our data lead the way for further dissection of the molecular mechanisms of implantation of the human embryo, and have implications for infertility, in vitro fertilization and contraception. q
Introduction
Blastocyst implantation is a complex process involving the tightly controlled and coordinated modulation of gene expression in the embryo and the endometrium. First, the endometrium must express a phenotype receptive to the blastocyst and vice versa, after which the blastocyst attaches to the lumenal epithelium of the endometrium via receptorligand interactions. The embryonic trophectoderm then penetrates the endometrial epithelium and underlying stromal extracellular matrix. Embryo priming and endometrial receptivity, characterised by the expression of molecules that participate in embryo attachment and invasion, are understood to be achieved via cooperative signalling pathways that operate between the blastocyst and the endometrium (Cross et al., 1994; Edwards, 1995) .
The implantation process has been widely studied in rodents, but the fundamental differences between the anatomy and physiology of the rodent and human female reproductive tracts do not necessarily allow direct extrapolation of functional information from rodent to human. The elucidation of the precise molecular mechanisms underlying implantation of the human blastocyst thus remains an intractable problem.
Many underlying causes of infertility can now be bypassed by in vitro fertilization. However, the consistently low pregnancy rate from this technique, despite the transfer of apparently healthy embryos into the uterine cavity, points to the disruption of events such as embryo implantation, that occur following embryo transfer, as a major cause of infertility (HFEA, 2000) . Implantation of the human blastocyst occurs during a restricted window of time which occurs in the mid-secretory stage of the menstrual cycle (day 6-8 post-fertilization).
Heparin-binding epidermal growth factor (HB-EGF) is a candidate molecule for facilitating endometrial receptivity and implantation. HB-EGF is a member of the epidermal growth factor (EGF) family and is synthesised as a transmembrane precursor (tm-HB-EGF) which may subsequently be cleaved by proteolytic processing to release a soluble form of the molecule (sol-HB-EGF), or it can remain bound to the membrane Higashiyama et al., 1991; Raab et al., 1994) . It has been shown previously to bind and activate two transmembrane receptors, the EGF receptor (HER1) and ErbB4 (HER4) (Elenius et al., 1997; Higashiyama et al., 1991; Higashiyama et al., 1992) and act as a juxtacrine and paracrine growth factor for many different cells Higashiyama et al., 1991; Higashiyama et al., 1995; Kiso et al., 1995; Takemura et al., 1997; Wilson et al., 1994) .
Previous studies suggest that HB-EGF has a function in implantation of rodent blastocysts (Das et al., 1994; Raab et al., 1996) . In particular, mouse myeloid cells over-expressing HB-EGF have been shown to adhere to mouse blastocysts via a heparin-dependent mechanism (Raab et al., 1996) . In addition, beads soaked in sol-HB-EGF placed in the uterus of pseudopregnant mice elicited local decidual responses that mimic those induced by the blastocyst (Paria et al., 2001) , indicating that HB-EGF secreted locally at the site of implantation may have some function in the decidualization process.
There is a growing evidence to suggest that HB-EGF also has an important function in human blastocyst development and uterine receptivity. We have shown previously that sol-HB-EGF increases the rate of blastocyst hatching (Martin et al., 1998) . The levels of endometrial HB-EGF mRNA increase in the secretory stage of the menstrual cycle, with highest levels immediately prior to the implantation window. Similarly, the levels of sol-HB-EGF protein in the lumenal and glandular epithelium are elevated during the window of implantation (Leach et al., 1999) .
Here we report the expression of tm-HB-EGF on the lumenal surface of the human endometrial epithelium at the time of implantation, and its receptor, ErbB4, on the trophectoderm of human peri-implantation blastocysts. We demonstrate in two different in vitro models for implantation that tm-HB-EGF mediates the attachment of human blastocysts.
Materials and methods

Tissue samples and immunohistochemistry
Tissue samples were collected in accordance with the requirements of the Oxfordshire Research Ethics Committee (OxREC). Endometrial samples were obtained from patients aged 20-46 years undergoing hysterectomy for benign indications or sterilization, who had a regular 26-33 days menstrual cycle, and who had received no hormonal medication in the preceding 3 months. The cycle stage of the endometrium was assessed according to Noyes's criteria (Noyes et al., 1950) and samples exhibiting pathologies such as fibroids were excluded. Tissue samples obtained from 16 patients (eight from proliferative and eight from secretory stage endometrium) were processed and stained as described previously (Biddolph and Jones, 1999) . Briefly, tissues were embedded in paraffin wax and sections stained with 10 mg/ml goat anti-rabbit HB-EGF precursor (Santa Cruz Biotechnology Inc, USA), and horseradish peroxidase (HRP)-conjugated anti-goat immunoglobulin G (IgG). Bound antibodies were detected with HRP substrate diaminobenzidine tetrachloride (DAB) (Sigma Ltd., UK). Control sections were treated with the same primary antibody preincubated with HB-EGF antigenic peptide.
Preparation of HB-EGF-Fc fusion protein for embryo attachment experiments
The extracellular region of HB-EGF coding for amino acids 1-149 (Higashiyama et al., 1992) was amplified by polymerase chain reaction (PCR) and cloned into the pIG1 vector (Simmons, 1993) . The nucleotide sequence of the construct was confirmed by automated DNA sequencing (DNA Sequencing Service, Sir William Dunn School of Pathology, University of Oxford). The soluble HB-EGFFc fusion protein was expressed and purified as described before (Hudson et al., 1996) . Purified protein was analysed by 7.5% reducing sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting using standard protocols. Detection of HB-EGF in Western blots was achieved by the use of 4 mg/ml goat anti-human HB-EGF antibody (R & D Systems, UK) and 1/8000 dilution rabbit anti-goat HRP-conjugated antibody (Sigma Ltd., UK). The sequence of the recombinant HB-EGF was confirmed by automated protein sequencing. For the blastocyst attachment experiments, 13 mm glass coverslips (Chance Propper Ltd, UK) were coated with 1 mg/ml protein A (Sigma Ltd., UK) in phosphate-buffered saline (PBS) for 24 h at room temperature, and blocked with 3% bovine serum albumin (BSA) (Sigma Ltd., UK) in PBS for 2 h at room temperature. Coverslips were washed in PBS and incubated with 2 mg/ml HB-EGF-Fc fusion protein in PBS for 2 h at room temperature. Excess HB-EGF-Fc was removed by extensive washing in PBS and coverslips were stored for a maximum of 2 days in PBS at 48C before use in the embryo attachment experiments.
Preparation of CHO cells expressing tm-HB-EGF
HB-EGF cDNA was prepared by PCR amplification of the region of cDNA encoding amino acids 1-208 of HB-EGF (Higashiyama et al., 1992) . The primers (5 0 TATCTA-GACCACCATGAAGCTGCTGCCGTCGGTG and 3 0 TATCTAGATCAGTGGGAATTAGTCAT) introduced optimised Kozak sequence (Kozak, 1986) and XbaI sites which were used for cloning into pEE14 vector (CellTech Ltd, UK). The nucleotide sequence of the construct was confirmed by automated DNA sequencing as above. Stable transfectants expressing tm-HB-EGF (CHO/HB-EGF) were generated by standard CaPO 4 transfection techniques. A control cell line was generated using a similar protocol by which cells were transfected with the pEE14 vector alone (CHO/vector). Selection for amplification was performed in one step by incubation in 25 mM methionine sulfoximine (MSX; Sigma Ltd., UK) and cell lines were maintained in Glasgow Essential Minimum Medium (GMEM) (First Link Ltd., UK) containing 10% dialysed fetal calf serum (FCS), penicillin, streptomycin and 25 mM MSX at 378C in 5% CO 2 . Cultures of stable CHO cell lines (CHO/HB-EGF or CHO/vector) were trypsinized according to standard procedures, split 1:3 and plated onto 13 mm glass coverslips. When the cells reached confluence, the cultures were washed twice in 2 mM NaCl in PBS and fixed with 3% paraformaldehyde in PBS for 5 min. The fixed cells were washed twice in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS, washed extensively in PBS and used in the embryo attachment assays described below, or stained for tm-HB-EGF. Immunofluorescent detection of tm-HB-EGF was achieved by incubation in 4 mg/ml goat anti-tm-HB-EGF (recognising an intracellular epitope; Santa Cruz Inc., US) for 1 h at room temperature, washed in PBS and incubated in 15 mg/ml rabbit anti-goat fluorescein isothiocyanate (FITC)-conjugated IgG (Sigma Ltd., UK). Goat IgG was used in negative controls as appropriate. Coverslips were washed in PBS and mounted in Vectashield medium with 4 0 ,6-diamidino-2-phenylindole-2
HCl (DAPI) (Vector Laboratories, UK). The staining was observed using an LEITZ DMRBE microscope (Leica Wetzlar, Germany) and Openlab imaging software (Improvision, UK).
Human embryos
The experiments were performed with ethical approval from OxREC and the Human Fertilisation and Embryology Authority (HFEA). All the embryos in this study were derived from cryopreservation and donated for research with informed consent by couples attending the Oxford Fertility Unit, John Radcliffe Hospital, Oxford. Embryos derived after cryopreservation give rise to ,20% live births, compared to ,30% from non-frozen embryos in the Oxford Fertility Unit. Ovarian stimulation, IVF and embryo culture until day 2 were performed as previously described (Martin et al., 1998) . Day 2 human embryos were frozen in a Planer Cryo 10 Series III freezer (Planer Products Ltd, UK) and thawed according to standard protocols (Horne et al., 1997; Ziebe et al., 1998) . Thawed embryos were assessed according to morphology and those displaying $50% blastomere survival were selected for use in these experiments. These embryos were washed in pre-equilibrated complex serumfree medium (CSFM3 (Martin et al., 1998) ) containing 2.5% HSA (Bioproducts Laboratory, UK) and cultured until day 6. The embryos were cultured in 15 ml CSFM3 until they reached the expanded blastocyst stage (days 5-7). The majority of blastocysts (85%) did not hatch naturally, in which case their zona pellucida were digested by exposure to acid Tyrode's solution and they were then washed by incubation in PBS/0.05% BSA for 5 min. Similar numbers of naturally hatched and Tyrode's treated blastocysts were used for each experimental procedure. For this study, we used 26 embryos grade A-C (54% A, 19% B and 27% C) (Martin et al., 1998) , and similar numbers were allocated randomly to each experimental procedure.
Embryo attachment assays
Human blastocysts were transferred onto either CHO/ HB-EGF cells, control CHO/vector cells, or HB-EGF-Fccoated coverslips (described above) and cultured in 500 ml of CSFM3 supplemented with 2.5% HSA. Embryos in negative control experiments for HB-EGF-Fc-attachment experiments were incubated in CSFM3 containing 2 mg/ ml sol-HB-EGF (R&D Systems, UK). The blastocysts were cultured for 24-48 h and assessed for attachment every 4-12 h by gently shaking the culture dish three times for 3 s each. Observation was performed under a stereo microscope at £ 100 magnification. Blastocysts were photographed after 24 h culture and their average diameter was assessed by measuring one vertical and one horizontal diameter (mm) from each blastocyst on the photographic image, and expressed as mm.
Immunofluorescent labelling of human blastocysts
Blastocysts were fixed, permeabilized and stained using a modification of the protocol described above for staining of CHO cells. Blastocysts were treated with mouse anti-human ErbB4 antibodies, clone HFR-1 (Srinivasan et al., 1999) and rabbit anti-human EGF receptor antibodies (Santa Cruz UK). Negative controls were treated with mouse IgG (Beckman Coulter, UK) or rabbit IgG (Sigma Ltd, UK), and FITC-conjugated donkey anti-mouse antibody and Texas Red-conjugated donkey anti-rabbit antibody (Jackson Immunoresearch Laboratories Inc., USA) were used as secondary antibodies. Embryos were mounted in Vectashield containing DAPI. Deconvolution of 5 mm optical sections through the stained blastocysts was performed using Openlab software (Improvision Ltd., UK).
Statistical analyses
The numbers of blastocysts attached and not attached were compared using Fisher's exact test. Blastocyst diameter measurements were analysed using the unpaired t-test.
Results
3.1. tm-HB-EGF is expressed on the apical surface of the lumenal epithelium in the human endometrium at the time of implantation A possible function for HB-EGF in embryo attachment during the early stage of implantation would predict that the tm form of HB-EGF must be expressed on the lumenal edge of the endometrium at the time of implantation. We performed an analysis of tm-HB-EGF expression in the human endometrium. We observed that tm-HB-EGF levels were low in the stroma and epithelium of proliferative stage endometrium ( Fig. 1(a) ). However, sections of early-mid secretory endometrium showed staining in both the lumenal epithelium and adjacent glands and stroma ( Fig. 1(b) ). High magnification revealed discrete staining for tm-HB-EGF on the apical surface of the lumenal epithelium ( Fig. 1(c) ). Staining was also visible on the basal surfaces of both lumenal and glandular epithelium. Control sections, treated with anti-tm-HB-EGF antibodies pre-adsorbed with the antigen peptide, were negative ( Fig. 1(d) ).
HB-EGF mediates attachment of human blastocysts in a solid phase model of implantation
Having established that the spatio-temporal pattern of expression of tm-HB-EGF is consistent with its putative function in implantation, we performed functional assays for embryo attachment using human blastocysts ( Fig. 2 ; Table 1 ). The ectodomain of tm-HB-EGF was expressed in HEK293T cells as a fusion protein with the N-terminus of Fc region of human IgG (HB-EGF-Fc). This facilitated unidirectional anchorage of the HB-EGF to protein Acoated coverslips, via the Fc tag. Analysis of the recombinant protein by reducing SDS-PAGE and western blot revealed multiple bands between ,38-42 kDa ( Fig.  2(a,b) ) which represented the products of N-terminal heterogeneity of HB-EGF described previously (Higashiyama et al., 1992) , and was confirmed by protein sequencing. Eleven human-hatched blastocysts at day 6 (n ¼ 9) or day 7 (n ¼ 2) development were placed on coverslips coated with HB-EGF-Fc either in the presence (n ¼ 3) or absence (n ¼ 8) of soluble HB-EGF (sol-HB-EGF) (see Table 1 ). Seven of the eight blastocysts attached themselves to HB-EGF-Fc in the absence of soluble HB-EGF. Five of the seven blastocysts that attached to HB-EGF-Fc remained expanded after 48 h in culture, as shown in Fig. 2(c) . None of the three blastocysts cultured on HB-EGF-Fc in the competition experiment with sol-HB-EGF, attached after 24-48 h (Fig. 2(d) ; Table 1 ).
tm-HB-EGF mediates attachment of human blastocysts in an in vitro cellular model of implantation
The function of tm-HB-EGF expressed on the cell membrane, and thus in the context of other cell surface molecules, was tested using CHO cells overexpressing tm- Fig. 3(a, b) ). It is important to note that the CHO/HB-EGF cells were fixed prior to use in the embryo attachment assays, and thus, in these experiments, the tm-HB-EGF was presented in the absence of any dynamic or signalling responses that may occur in vivo, and that may further influence embryo attachment and invasion responses. Fifteen hatched human blastocysts (13 at day 6 and two at day 7 development) were placed on fixed monolayer cultures of CHO/HB-EGF (n ¼ 10) or CHO/vector (n ¼ 5). Eight of the 10 blastocysts on CHO/HB-EGF were attached to the cells, whereas none of the five blastocysts that were cultured on CHO/vector attached during 24-48 h of culture (Fig. 3(c, d) ). These results were thus similar to those obtained for blastocyst attachment to HB-EGF-Fc (above and Table 1 ). Furthermore, five of the eight blastocysts that attached to CHO/HB-EGF remained expanded for the 24-48 h culture period (Fig. 3(c, e) ). However, in contrast to the blastocysts that did not attach to HB-EGFFc in the presence of sol-HB-EGF, none of the five unattached blastocysts cultured on CHO/vector (cultured in the absence of sol-HB-EGF) remained expanded after 24-48 h and all degenerated (Fig. 3(d) ; Table 1 ) with no distinguishable inner cell mass even at high magnification (compare Fig. 3(e) with Fig. 3(f) ).
HB-EGF (CHO/HB-EGF;
HB-EGF sustains blastocyst expansion
The mean diameters of blastocysts cultured in the presence or absence of HB-EGF are presented in Fig. 4 . The mean diameter of blastocysts that attached to either CHO/HB-EGF or HB-EGF-Fc (75.7^6.2 mm, n ¼ 15) was significantly higher than that of blastocysts that did not attach to HB-EGF or that were plated onto CHO/vector (29.4^1.9 mm; n ¼ 7; P # 0:01). This is consistent with our previous data demonstrating that cultured human blastocysts maintain their viability better when attached to a substrate compared to blastocysts maintained in suspension (Dokras et al., 1991) . The effect of blastocyst exposure to either tm-HB-EGF, by being attached to immobilized HB-EGF, (HB-EGF-Fc and CHO/HB-EGF) or sol-HB-EGF (HB-EGF-Fc 1 sol-HB-EGF) on blastocyst diameter was assessed (Fig. 4) . The mean diameter of blastocysts that attached to HB-EGF-Fc or CHO/HB-EGF, or were plated onto HB-EGF-Fc in the presence of sol-HB-EGF, (i.e. blastocysts interacting with either form of HB-EGF but not necessarily attached) was 73.9^5.6 mm (n ¼ 18). This is significantly higher than the mean diameter of blastocysts that did not attach and that were cultured in the absence of sol-HB-EGF (29.4^1.9 mm; n ¼ 7; P # 0:01). The mean diameter of unattached blastocysts cultured in the presence of sol-HB-EGF (mean ¼ 60.67^12.7 mm; n ¼ 3) was also significantly higher than that of unattached blastocysts cultured in the absence of sol-HB-EGF (P , 0:01).
HB-EGF receptors EGF-R1 and ErbB4 are differentially expressed in human peri-implantation blastocysts
Previous studies have shown that functional HB-EGF receptors are formed by the EGF receptor and ErbB4 (Elenius et al., 1997) . Having established that tm-HB-EGF or HB-EGF-Fc can mediate the attachment of human blastocysts in our in vitro model systems, we investigated the expression of the HB-EGF receptors, EGF receptor and ErbB4, in hatched, human peri-implantation blastocysts. Embryos were triple-stained using anti-EGF receptor, antiErbB4 and nuclear stain (DAPI), as represented in Fig. 5 . Staining for the EGF receptor was largely localised in the inner cell mass and was strongly positive (Fig. 5(a) ). Conversely, staining for ErbB4 was not detected in the inner cell mass, but was intense and distinct on the outer surface of the trophectoderm (Fig. 5(b) ). Visualization of the merged images confirmed that the expression of EGF 5(d) ).
Discussion
Experimental investigation of the mechanisms that mediate human implantation is complicated by the inevitable difficulties of working with physiologically relevant material. Here we have determined a function for the transmembrane form of HB-EGF in the implantation of the human blastocyst using a combination of experimental approaches. We have shown that (i) tm-HB-EGF is expressed on the apical surface of the lumenal epithelium of the human endometrium at the time of implantation; (ii) peri-implantation human blastocysts attach specifically to the ectodomain of HB-EGF anchored either as an Fc-fusion protein in solid phase assays, or as a tm protein in transfected CHO cells, and (iii) the receptor for HB-EGF, ErbB4, is expressed on the surface of the trophectoderm of human peri-implantation blastocysts.
Previous studies have described the expression of sol-HB-EGF in the secretory stage of the menstrual cycle in the human endometrium (Leach et al., 1999; Yoo et al., 1997 ). Here we demonstrate distinct apical expression of tm-HB-EGF on the lumenal epithelium at the mid-secretory but not the proliferative stage of the menstrual cycle. Apical localisation of tm-HB-EGF is sustained on the lumenal and glandular epithelium during the secretory stage (our unpublished observations). We predict that this spatio-temporal pattern of tm-HB-EGF expression in the human endometrium facilitates the attachment of the human blastocyst in vivo, as we have demonstrated in our in vitro functional studies.
The data we present demonstrate a function for tm-HB-EGF in human blastocyst attachment in in vitro model systems, and are in agreement with previous studies in the mouse (Raab et al., 1996) . None of the blastocysts that attached to tm-HB-EGF in our assays exhibited trophoblast outgrowth or, in the CHO/HB-EGF experiments, invasion of the cell layer. One explanation for these results is that our model systems do not support these secondary implantation events. Fixation of the transfected CHO cells prior to the transfer of blastocysts to the CHO cell monolayer inhibits further dynamic responses to attachment, such as the formation of complexes between HB-EGF and other molecules, that might be involved in HB-EGF-mediated trophoblast outgrowth and invasion. However, a second explanation, as supported by the solid phase assays for tm-HB-EGF-Fc function is that the function of tm-HB-EGF in implantation is to mediate the primary event of embryo attachment and that additional molecules are required for downstream processes to occur.
Here we show that expression of ErbB4 in the human blastocyst is predominantly on the surface of the trophectoderm, in particular on the trophectoderm adjacent to the inner cell mass. Considered together, our data suggest that the interaction of tm-HB-EGF, localised on the apical surface of the lumenal epithelium in the endometrium, with ErbB4 mediates implantation of the human blastocyst. Furthermore, the differential localization of the EGF receptor and ErbB4 suggests that they may have distinct functions in peri-implantation blastocysts. We propose that, in the human, ErbB4 mediates implantation whilst the EGF receptor mediates the growth and/or the differentiation of the inner cell mass, as suggested for the mouse (Threadgill et al., 1995) . A previous report suggests a role for ErbB4 in the implantation of the mouse blastocyst (Paria et al., 1999) . However, targeted disruption of ErbB4 in the mouse does not prevent embryo implantation (Gassmann et al., 1995) . This may reflect species-specific differences in implantation between the rodent and the human, and/or promiscuity of the EGF-related family and its receptors in the implantation process in the mouse. In addition, the possibility that ErbB4 may have some chemotactic function (Elenius et al., 1997) in directing the blastocyst to the final implantation site in the endometrium, cannot be ruled out.
Finally, our data demonstrate that exposure to either solor tm-HB-EGF sustains blastocyst expansion. This indicates that the HB-EGF ligand potentiates the health and survival of human peri-implantation embryos, in addition to inducing progression of the development of human pre-implantation embryos as shown previously (Martin et al., 1998) .
The functional in vitro models we have described will provide a means to dissect further the specific functions of HB-EGF and its receptors in particular, and other ligandreceptor interactions in general, in human implantation. In addition, the data we present here define a target for new therapies for infertility and for potential strategies for the development of contraceptive agents. 
